CAR-T Cell Therapy - What's the Outlook?

There was a lot of excitement about off-the-shelf cell therapies, but maybe it's waned a little bit. It seems like particularly as the patient-specific CAR-T's have moved ahead into earlier lines of care that they've sort of got really settled into the market and are gaining ground. I think on cell therapy, when you think about autologous cell therapy, the dynamics have been that all the companies are getting their cost of goods down.